{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:10:18Z","timestamp":1791432618123,"version":"4.3.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1124\/dmd.31.6.731","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T01:03:50Z","timestamp":1054688630000},"page":"731-741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":283,"title":["THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN"],"prefix":"10.1016","volume":"31","author":[{"given":"S.J.","family":"Roffey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Comby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Jezequel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.R.","family":"Nedderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.K.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.31.6.731_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cpt1970111121","article-title":"The rate of decline of diphenylhydantoin in human plasma.","volume":"11","author":"Arnold","year":"1970","journal-title":"Clin Pharm Ther"},{"key":"10.1124\/dmd.31.6.731_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/j.1875-9114.1990.tb02561.x","article-title":"The triazole antifungal agents: a review of itraconazole and fluconazole.","volume":"10","author":"Bailey","year":"1990","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.31.6.731_bib3","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.40.8.1948","article-title":"In vitro studies of two triazole antifungal agents (UK-109, 496 and fluconazole) against Candida species.","volume":"40","author":"Barry","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/jac\/45.5.673","article-title":"Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model","volume":"45","author":"Chandrasekar","year":"2000","journal-title":"J Antimicrob Chem"},{"key":"10.1124\/dmd.31.6.731_bib5","first-page":"155","article-title":"Non linear theophylline pharmacokinetics.","volume":"18","author":"Dunn","year":"1984","journal-title":"Drug Intell Clin Pharm"},{"key":"10.1124\/dmd.31.6.731_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/AAC.40.1.86","article-title":"Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.","volume":"40","author":"George","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib7","first-page":"455","article-title":"Explanation of dose-dependent decline in diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.","volume":"3","author":"Gerber","year":"1972","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"10.1124\/dmd.31.6.731_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00003495-198937030-00003","article-title":"Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses.","volume":"37","author":"Grant","year":"1989","journal-title":"Drugs"},{"key":"10.1124\/dmd.31.6.731_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors.","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.31.6.731_bib10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.2042-7158.1994.tb03777.x","article-title":"Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties.","volume":"46","author":"Jezequel","year":"1994","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.31.6.731_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.41.1.13","article-title":"Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.","volume":"41","author":"Martin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib13","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.41.3.696","article-title":"Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.","volume":"41","author":"Murphy","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib14","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide-binding pigment of liver microsomes.","volume":"239","author":"Omura","year":"1964","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.31.6.731_bib15","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous-to-oral dose escalation regimens.","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib16","series-title":"Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sept 17\u201320; San Francisco, CA.","first-page":"125","article-title":"UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro","author":"Pye","year":"1995"},{"key":"10.1124\/dmd.31.6.731_bib17","series-title":"Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sept 17\u201320; San Francisco, CA.","first-page":"124","article-title":"UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: synthesis and SAR","author":"Richardson","year":"1995"},{"key":"10.1124\/dmd.31.6.731_bib18","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","article-title":"A new triazole, voriconazole (UK109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.","volume":"41","author":"Sanati","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.31.6.731_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/03602539109029764","article-title":"Species differences in metabolism and pharmacokinetics: are we close to an understanding?","volume":"23","author":"Smith","year":"1991","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.31.6.731_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0928-0987(00)00107-X","article-title":"Induction and drug development.","volume":"11","author":"Smith","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.31.6.731_bib21","series-title":"Glucuronic Acid: Free and Combined Chemistry, Biochemistry, Pharmacology and Medicine","first-page":"42","article-title":"Implications of the conjugation of drugs and other exogenous compounds","author":"Smith","year":"1966"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624026977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624026977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.31.6.731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T15:11:15Z","timestamp":1739891475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624026977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S0090955624026977"],"URL":"https:\/\/doi.org\/10.1124\/dmd.31.6.731","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"THE DISPOSITION OF VORICONAZOLE IN MOUSE, RAT, RABBIT, GUINEA PIG, DOG, AND HUMAN","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.31.6.731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2003 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}